SCHEMBL4363399

SCHEMBL4363399

COC(=O)[C@@H](N)CCCCNC(=O)OCc1ccccc1

nearest known ligand 0.67

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
DPP8 Q6V1X1 3/20 0.67
DPP7 Q9UHL4 3/20 0.67
ANPEP P15144 1/20 0.64
DPP4 P27487 2/20 0.62
DPP9 Q86TI2 2/20 0.62
SLC1A3 P43003 1/20 0.59
SLC1A1 P43005 1/20 0.59
HTT P42858 1/20 0.59
CA1 P00915 1/20 0.59
CA2 P00918 1/20 0.59
FOLH1 Q04609 3/20 0.57
TGM2 P21980 1/20 0.56
LMNA P02545 1/20 0.55
SMN1; SMN2 Q16637 1/20 0.55
KEAP1 Q14145 1/20 0.54
NFE2L2 Q16236 1/20 0.54
MMP2 P08253 1/20 0.54
MMP9 P14780 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10821457 1.00 DPP8 (0.67) DPP8DPP7ANPEPDPP4DPP9
SCHEMBL6356988 1.00 DPP8 (0.67) DPP8DPP7ANPEPDPP4DPP9
Hydrochloric Acid SCHEMBL6356943 0.99 DPP8 (0.65) DPP8DPP7ANPEPDPP4DPP9
Hydrochloric Acid SCHEMBL5189156 0.99 DPP8 (0.65) DPP8DPP7ANPEPDPP4DPP9
Hydrochloric Acid SCHEMBL3132219 0.99 DPP8 (0.65) DPP8DPP7ANPEPDPP4DPP9
SCHEMBL1586583 0.96 DPP8 (0.61) DPP8DPP7ANPEPDPP4DPP9
SCHEMBL12619410 0.96 DPP8 (0.61) DPP8DPP7ANPEPDPP4DPP9
SCHEMBL1586581 0.96 DPP8 (0.61) DPP8DPP7ANPEPDPP4DPP9
Hydrochloric Acid SCHEMBL28567293 0.95 DPP8 (0.60) DPP8DPP7ANPEPDPP4DPP9
Hydrochloric Acid SCHEMBL6624995 0.95 DPP8 (0.60) DPP8DPP7ANPEPDPP4DPP9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 116 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114315957-B Preparation method of polypeptide 深圳瑞德林生物技术有限公司 2023-07-07 CN claimed
CN-114315957-A Preparation method of polypeptide 深圳瑞德林生物技术有限公司 2022-04-12 CN claimed
US-20240238422-A1 Hypoimmunogenic Biotherapeutics ADAXION THERAPEUTICS, INC. 2024-07-18 US disclosed
WO-2024094098-A1 COMPOUND FOR DELIVERY SYSTEM AND USE THEREOF 益杰立科(上海)生物科技有限公司 2024-05-10 WO disclosed
CN-114315957-B Preparation method of polypeptide 深圳瑞德林生物技术有限公司 2023-07-07 CN disclosed
US-20230210110-A1 METHOD FOR INDUCING ENVIRONMENTAL STRESS TOLERANCE IN PLANTS AJINOMOTO CO., INC. (JP) 2023-07-06 US disclosed
US-20230210110-A1 METHOD FOR INDUCING ENVIRONMENTAL STRESS TOLERANCE IN PLANTS AJINOMOTO CO., INC. (JP) 2023-07-06 US disclosed
EP-3988561-B1 PREPARATION AND USE OF REACTIVE OXYGEN SPECIES SCAVENGER XWPHARMA LTD (KY) 2023-06-07 EP disclosed
EP-3988561-A1 PREPARATION AND USE OF REACTIVE OXYGEN SPECIES SCAVENGER XWPharma Ltd. (KY) 2022-04-27 EP disclosed
US-11312703-B2 Reactive oxygen species scavengers and use for treating diseases XWPharma Ltd. (KY) 2022-04-26 US disclosed
EP-3980052-A1 GLUCOSE-RESPONSIVE INSULIN CONJUGATES MERCK SHARP & DOHME CORP. (US) 2022-04-13 EP disclosed
EP-1263716-A2 AMINO ACID DERIVATIVES AS HIV ASPARTYL PROTEASE INHIBITORS Pharmacor Inc. (CA) 2002-12-11 EP disclosed
US-6455587-B1 AROMATIC SULFONYL DERIVATIVES PHARMACOR INC. (CA) 2002-09-24 US disclosed
WO-2001068593-A2 AMINO ACID DERIVATIVES AS HIV ASPARTYL PROTEASE INHIBITORS PHARMACOR INC. (CA) 2001-09-20 WO disclosed
US-5494898-A DIQUATERNARY TRIPEPTIDES OHMEDA PHARMACEUTICAL PRODUCTS DIVISION INC. (US) 1996-02-27 US disclosed
US-H1312-H Method for the preparation of gyk-dtpa CYTOGEN CORPORATION (US) 1994-05-03 US disclosed
EP-0313969-B1 TRIPEPTIDE DERIVATIVES AND ANTIPLASMIN AGENTS CONTAINING THE SAME NITTO BOSEKI CO., LTD. (JP) 1993-03-24 EP disclosed
EP-0498941-A2 Peptide skeletal muscle relaxants BOC Health Care, Inc. (US) 1992-08-19 EP disclosed
US-4883863-A FROM LYSINE OR TYROSINE, PHENYLALANINE AND LYSINE, HEMOSTATIC AGENTS NITTO BOSEKI CO., LTD. (JP) 1989-11-28 US disclosed
EP-0313969-A2 Tripeptide derivatives and antiplasmin agents containing the same NITTO BOSEKI CO., LTD. (JP) 1989-05-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230210110-A1 METHOD FOR INDUCING ENVIRONMENTAL STRESS TOLERANCE IN PLANTS DAO, ALAD, BCAT1 DPP8 1787/4885DPP7 2381/4885ANPEP 51/4885
US-11312703-B2 Reactive oxygen species scavengers and use for treating diseases GSR, TXNRD2, GPX1 DPP8 3553/4885DPP7 3005/4885ANPEP 3786/4885
US-20240238422-A1 Hypoimmunogenic Biotherapeutics FCGR3B, CD47, IL2 DPP8 2388/4885DPP7 1836/4885ANPEP 2185/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.